Participants in the study will be assigned to different groups to receive either the combined pill or the individual medications, along with a program where nurses provide educational support. The study will follow these individuals for one year after they are discharged from the hospital to see if this combined approach helps them stay consistent with their daily medication routine. The course of the study involves regular follow-ups to monitor how well the treatment plan is being followed and to observe various health factors.

During the study, participants may receive inclisiran via a subcutaneous injection, which is a needle shot just under the skin, or a placebo. In addition to the study medication, participants will continue to take background treatments, which include medications like rosuvastatin or atorvastatin. These are types of statins used to manage cholesterol levels. The study will monitor various changes in blood levels, including PCSK9, apoB, VLDL, and triglycerides, to understand how the treatment affects the body over time.

The course of the study involves monitoring participants from the time they are in the hospital through a period of 150 days. Medical professionals will observe how the different treatments influence cholesterol levels and check for any side effects that may occur during the treatment period.

The purpose of this study is to see if semaglutide can reduce inflammation inside the plaques that build up in the heart arteries. Inflammation is a process where the body’s immune system responds to damage or disease, and in this case, certain immune cells called macrophages collect in the plaques. The study will measure whether the medication can decrease the amount of these macrophages in the plaques. To do this, doctors will use a special imaging technique called optical coherence tomography, which is a way of taking detailed pictures of the inside of the arteries using light waves. This procedure allows doctors to see the structure and composition of the plaques.

During the study, participants will receive either semaglutide or a placebo for 24 weeks. At the beginning and end of this period, doctors will perform optical coherence tomography to examine the plaques in the arteries that are not the main blocked artery that caused the heart problem. The study will look at various features of these plaques, including their size, thickness of the covering layer, and the presence of different materials like fat and calcium. Doctors will also monitor blood sugar control, body weight, any heart-related events, and any side effects that may occur during the treatment period.

Participants in this study will have experienced a heart attack affecting the front or side wall of the heart. They will be treated at the study center and must be stable enough to participate, meaning their blood pressure and heart rate are within certain ranges. The study medication will be given through a vein continuously for 24 hours, starting before the procedure to open the blocked arteries and continuing during and after the procedure. The main goal is to see how many enrolled patients can receive the full 24-hour infusion of Landiolol with no single break longer than one hour.

During the study, doctors will closely monitor participants for any irregular heart rhythms, changes in heart function, and blood pressure. Blood tests will be taken at different times to measure substances that indicate heart damage and function. Heart activity will be monitored using electrocardiograms at admission and at regular intervals up to 90 days. An ultrasound examination of the heart will be performed to measure how well the heart is pumping at the beginning of the study and again after 90 days. The study will also track any heart-related problems, hospital readmissions, and overall health outcomes for up to six months after treatment.

The purpose of this study is to find out whether older patients who are 65 years or older with iron deficiency after experiencing an acute coronary syndrome have a better quality of life when they receive intravenous iron treatment compared to those who do not receive it. Quality of life refers to a person’s overall wellbeing and how they feel in their daily activities. The study will look at quality of life changes after 6 months and 12 months of follow-up.

Patients who take part in this study will be randomly assigned to either receive the intravenous iron treatment or not receive it. The study will follow patients for 12 months and will measure various health outcomes including changes in quality of life scores, changes in frailty levels, and the occurrence of heart-related problems such as heart failure requiring hospital admission, heart attack, or stroke. The study will also look at markers in the blood related to iron levels, inflammation, and aging in some patients. Researchers will track how patients are doing throughout the year to see if the iron treatment makes a difference in their health and wellbeing.

The purpose of the study is to evaluate whether using a lower dose of prasugrel alone is both feasible and safe for these patients after their procedure. Participants in the study will receive the reduced dose of prasugrel as their only antiplatelet medication, which helps prevent blood clots from forming in the arteries.

Throughout the study, researchers will monitor patients for various health outcomes, including complications like bleeding events and heart-related issues. They will also assess how satisfied patients are with the treatment and how well they adhere to the medication regimen.

The research compares single antiplatelet therapy (SAPT) with dual antiplatelet therapy (DAPT). Antiplatelet medications help prevent blood clots from forming. The purpose is to determine if using just one antiplatelet medication is as effective as using two in preventing complications after the procedure, while potentially reducing bleeding risks.

The study will follow patients for 12 months after their procedure to track outcomes such as death from any cause, the need for additional procedures on the treated blood vessel, and heart attacks related to the treated vessel. Quality of life and functional status will be assessed using questionnaires at different timepoints throughout the study.

The purpose of the study is to determine if using an implantable device to monitor heart activity and guide anticoagulant treatment is safer in terms of reducing bleeding events compared to the standard approach. The study will involve the use of a small device placed inside the body that can send heart activity data to doctors remotely. This will help in deciding the best way to manage the anticoagulant treatment.

Participants in the study will be monitored over a period of two years. During this time, the occurrence of any bleeding events and other heart-related events will be recorded. The study aims to provide insights into whether this new method of monitoring and treatment can improve safety and outcomes for patients with these heart conditions.

Participants in the study will be randomly assigned to one of the treatment strategies or a standard treatment group. The study will last for up to 12 months, during which time participants will take the medication as prescribed and attend regular check-ups. The main goal is to monitor the safety of the treatments, particularly looking at any bleeding events that may occur. Bleeding is a known risk with antiplatelet drugs, and the study will track different types of bleeding, such as those that require medical attention or are life-threatening.

In addition to monitoring bleeding, the study will also look at other important health outcomes, such as heart attacks, strokes, and overall survival. The results will help determine which treatment strategy is safest and most effective for people with Acute Coronary Syndrome. This information could lead to improved treatment options for patients with this heart condition in the future.

Participants in the study will be randomly assigned to one of the two treatment groups. The study will monitor the occurrence of any major or significant bleeding events, as well as other heart-related events such as heart attacks, strokes, or the need for additional heart procedures. The study aims to determine if the dual therapy is as safe and effective as the triple therapy in managing these conditions.

The trial will take place over a period of time, with participants receiving their assigned treatment and being regularly monitored by healthcare professionals. The study will help to provide valuable information on the best treatment options for patients with these heart conditions, potentially improving care and outcomes for future patients.

The purpose of the study is to observe and compare the effects of these two treatment combinations in real-world settings. Participants will be randomly assigned to receive one of the two therapies. The study will last for about 12 months, during which the main focus will be on monitoring any bleeding events that occur. Additionally, the study will look at other important outcomes such as heart attacks, strokes, and any instances of blood clots forming in the stents used during PCI.

Throughout the study, participants will be closely monitored to ensure their safety and to gather data on the effectiveness of the treatments. The goal is to better understand which combination of medications provides the best balance between preventing blood clots and minimizing the risk of bleeding in patients with ACS who have undergone PCI.

The purpose of the study is to assess the safety and effectiveness of this treatment approach compared to the current standard treatment, which involves using a combination of medications to prevent blood clots. The study will follow patients for a period of 15 months to monitor for any major heart or brain events, such as heart attacks or strokes, as well as any significant bleeding events. The trial will also compare the outcomes of using the P2Y12 inhibitor alone for one month, followed by the DOAC alone for a longer period, against the standard treatment that involves multiple medications over several months.

Participants in the study will receive either the new treatment approach or the standard treatment. The study will help determine if the new approach is as safe and effective as the current standard. This research is important for improving treatment options for patients with atrial fibrillation who have undergone PCI, potentially leading to better health outcomes and fewer complications.

Participants in the study will be randomly assigned to receive either the short-term or the 12-month treatment. The study will monitor for any bleeding events and major heart or brain-related issues, such as heart attacks or strokes, during the treatment period. The goal is to determine if the shorter treatment is as safe and effective as the longer one. The study will also look at other factors, such as the rate of stent-related problems and the overall quality of life of the participants.

This trial is expected to run until the end of 2028, with recruitment starting in September 2024. Participants will be closely monitored throughout the study to ensure their safety and to gather important data on the effectiveness of the treatment options being tested. The findings from this study could help improve treatment strategies for patients with acute coronary syndromes in the future.

The purpose of the study is to analyze the level of systolic blood pressure (the top number in a blood pressure reading) and LDL cholesterol (often referred to as “bad” cholesterol) in the same patient during two different periods. One period involves treatment with the Trinomia polypill for three months, and the other involves treatment with the individual components for three months. This approach helps to understand how the combination pill compares to taking the medications separately.

Participants in the study will take the medications orally, as they are available in capsule or tablet form. The study will last for a total of six months, with patients switching between the polypill and the separate medications. The trial aims to provide insights into the best way to manage heart disease risk factors, potentially improving treatment strategies for patients with ischemic heart disease, a condition where the heart’s blood supply is reduced due to narrowed arteries.

The purpose of the study is to evaluate whether metformin can help reduce the need for additional unplanned procedures to restore blood flow to the heart in patients who have already had PCI due to ACS. Participants in the study will be given metformin in the form of a coated tablet, which they will take orally. The study will monitor the effects of metformin over a period of time to see if it can help prevent further heart-related issues.

Throughout the study, researchers will observe participants to see if there is a reduction in the need for further heart procedures, as well as monitor for any occurrences of heart-related deaths, deaths from any cause, non-fatal heart attacks, or non-fatal strokes. The study aims to provide valuable information on the potential benefits of metformin for patients with acute coronary syndrome who are not diabetic.

The purpose of the study is to determine if switching from the more powerful antiplatelet agents, prasugrel and ticagrelor, to clopidogrel, with guidance from a device called VerifyNow, can have a positive effect on treating ACS. The VerifyNow device measures how well platelets are being inhibited, or stopped, from forming clots. Participants in the study will take these medications in the form of film-coated tablets, which are taken orally, meaning they are swallowed. The study will last for up to 12 months, during which time the effects of the medication switch will be monitored.

Throughout the study, researchers will look at the occurrence of certain heart-related events, such as heart attacks, strokes, and bleeding incidents. These are referred to as Net Adverse Cardiac Events (NACE). The study aims to see if the change in medication can reduce these events over a 12-month period. The results will help determine the best approach to using these medications for people with ACS.

The purpose of the study is to evaluate how different doses of these antiplatelet drugs affect platelet reactivity, which is how well the platelets respond to the medication. The study will compare lower doses of Prasugrel (5 mg), Ticagrelor (60 mg twice daily), and Clopidogrel (75 mg) with the full doses of Prasugrel (10 mg) and Ticagrelor (90 mg twice daily). The goal is to find out which treatment helps achieve the best balance in platelet activity, known as optimal platelet reactivity, without causing excessive bleeding.

Participants in the study will take the medications for a period of up to six months. During this time, their platelet reactivity will be monitored to see how the medications are working. The study will also track any bleeding events and other health outcomes, such as heart attacks or strokes, to understand the overall safety and effectiveness of the treatment regimens. This research aims to improve treatment strategies for patients with Acute Coronary Syndrome who are at high risk of bleeding, ensuring they receive the most effective and safe care possible.

Participants in the study will be given either the standard treatment or a new treatment strategy involving Lixiana. The study will compare the safety and effectiveness of these treatments by looking at the risk of bleeding and the occurrence of heart-related events like heart attacks or strokes. The study will last for several weeks, with follow-ups to check on the participants’ health and any side effects they might experience.

The trial aims to provide valuable information on how to best manage patients with these heart conditions, ensuring they receive the safest and most effective treatment. The results will help doctors make informed decisions about using Lixiana in patients with atrial fibrillation and heart syndromes, especially after they have had a PCI procedure.

The purpose of the study is to find out if stopping aspirin can reduce the risk of bleeding without increasing the risk of heart-related problems like heart attacks or strokes. Participants in the study will be monitored over a period of time to see if they experience any major or minor bleeding or other heart-related events. The study aims to compare the outcomes of patients who continue taking aspirin with those who do not, to see if the latter group experiences less bleeding while still being protected from heart issues.

Throughout the study, participants will be given either the aspirin medication or a placebo, and their health will be closely observed. The study will last for up to 12 months, during which time the researchers will collect data on any bleeding incidents and heart-related events. The goal is to determine if omitting aspirin is a safe and effective option for patients with Non-ST-segment elevation acute coronary syndrome.

The purpose of the study is to determine if milvexian can effectively lower the risk of major adverse cardiovascular events, such as heart attacks, strokes, or cardiovascular-related deaths, when added to the usual care. Participants in the study will be randomly assigned to receive either milvexian or a placebo, and they will continue their regular heart medications. The study will last for a period of up to 48 weeks, during which participants will take the study medication orally in the form of film-coated tablets.

Throughout the study, participants will be monitored for any heart-related events and overall health. The goal is to see if milvexian can provide additional protection against serious heart problems compared to the placebo. This research aims to improve the understanding of how to better prevent recurrent cardiovascular events in patients who have recently suffered from a heart attack.

The purpose of the study is to assess both the risk of heart-related problems and the risk of bleeding when using Clopidogrel in this way. Participants will be monitored for six months after their PCI procedure. During this time, researchers will look at the occurrence of events such as heart attacks, strokes, and any bleeding issues. The study will also compare these outcomes to those of patients who might receive other treatments, including a placebo.

Throughout the study, participants will take Clopidogrel in the form of film-coated tablets. Another medication, Acetylsalicylic Acid, commonly known as aspirin, may also be used in some cases. The study aims to provide valuable information on the safety and effectiveness of Clopidogrel for patients with these heart conditions, helping to guide future treatment decisions.